Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Apollomics Inc Cl A (APLM)

Apollomics Inc Cl A (APLM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
Apollomics Announces $10 Million Private Placement Transaction GlobeNewswire - Tue Aug 11, 3:35PM CDT

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Announces $10 Million Private Placement Transaction GlobeNewswire - Tue Aug 11, 3:35PM CDT

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Regains Full Compliance with Nasdaq Listing Requirements GlobeNewswire - Mon Jul 13, 7:00AM CDT

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Regains Full Compliance with Nasdaq Listing Requirements GlobeNewswire - Mon Jul 13, 7:00AM CDT

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia GlobeNewswire - Wed Jun 24, 3:15PM CDT

FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia GlobeNewswire - Wed Jun 24, 3:15PM CDT

FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress GlobeNewswire - Mon Apr 27, 7:00AM CDT

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress GlobeNewswire - Mon Apr 27, 7:00AM CDT

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Inc. Announces $2.0 Million Bridge Financing GlobeNewswire - Wed Apr 1, 6:00AM CDT

FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)
Apollomics Inc. Announces $2.0 Million Bridge Financing GlobeNewswire - Wed Apr 1, 6:00AM CDT

Apollomics Inc. Announces $2.0 Million Bridge Financing...

APLM : 27.01 (+0.26%)
APLMW : 0.0114 (-17.39%)

Barchart Exclusives

How to Play SKHY Stock as SK hynix Looks to Build a New Plant in Japan Barchart - 19 minutes ago
SK hynix could be laying the groundwork for its next growth phase with its potential Japan expansion. Is SKHY now a buy, sell, or hold? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.